Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer.
Prostate
; 84(8): 747-755, 2024 Jun.
Article
em En
| MEDLINE
| ID: mdl-38544345
ABSTRACT
BACKGROUND:
Elevated circulating growth differentiation factor (GDF15/MIC-1), interleukin 4 (IL4), and IL6 levels were associated with resistance to docetaxel in an exploratory cohort of men with metastatic castration-resistant prostate cancer (mCRPC). This study aimed to establish level 2 evidence of cytokine biomarker utility in mCRPC.METHODS:
IntVal Plasma samples at baseline (BL) and Day 21 docetaxel (n = 120). ExtVal Serum samples at BL and Day 42 of docetaxel (n = 430). IL4, IL6, and GDF15 levels were measured by ELISA. Monocytes and dendritic cells were treated with 10% plasma from men with high or low GDF15 or recombinant GDF15.RESULTS:
IntVal Higher GDF15 levels at BL and Day 21 were associated with shorter overall survival (OS) (BL; p = 0.03 and Day 21; p = 0.004). IL4 and IL6 were not associated with outcomes. ExtVal Higher GDF15 levels at BL and Day 42 predicted shorter OS (BL; p < 0.0001 and Day 42; p < 0.0001). Plasma from men with high GDF15 caused an increase in CD86 expression on monocytes (p = 0.03), but was not replicated by recombinant GDF15.CONCLUSIONS:
Elevated circulating GDF15 is associated with poor prognosis in men with mCRPC receiving docetaxel and may be a marker of changes in the innate immune system in response to docetaxel resistance. These findings provide a strong rationale to consider GDF15 as a biomarker to guide a therapeutic trial of drugs targeting the innate immune system in combination with docetaxel in mCRPC.Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Biomarcadores Tumorais
/
Fator 15 de Diferenciação de Crescimento
/
Neoplasias de Próstata Resistentes à Castração
/
Docetaxel
/
Antineoplásicos
Limite:
Aged
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Prostate
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Austrália